A Google project to develop nanoparticles that can detect cancer cells inside the body is a useful contribution but faces major hurdles, experts said on Wednesday.

Google X Lab, a special projects unit, on Tuesday said the idea is to use tailored nanoparticles - particles measured in billionths of a metre - that would stick to cancerous cells or cancerous piece of DNA.
They would also adhere to fatty deposits in the blood that can be signatures of an impending stroke or heart attack. The particles would be swallowed in pills and thus taken into the bloodstream.
Magnetised, the particles could be drawn to a wearable device such as a wristband, where they would be counted. Other labs are already hard at work at exploring the potential nanoparticles, experts noted.
"The idea isn't new," said Laurent Levy, founder and chairman of a French company, Nanobiotix, which is looking at the use of nanoparticles in cancer radiotherapy.
"It's not science fiction -- it is achievable," he told AFP, saying that the technology is likely to start coming on stream within a decade.
Advertisement
The work means that existing scanning technology could be used.
Advertisement
"Some doctors feel that even though MRI scanners are effective at spotting large tumours, they are perhaps not as good at detecting smaller tumours in the early stages."
Like any medical innovation, diagnostic nanoparticles will have to be closely vetted for safety and effectiveness. One familiar hurdle in this field is "false positives," when a test wrongly says there is cancer.
"False positives" have dogged the PSA test for prostate cancer.
Higher levels of prostate-specific antigen (PSA), a protein produced by the prostate gland, are the telltale sought in the test -- but they can surge even when a man does not have cancer.
And even an accurate test for cancer is not in itself a requirement that the person needs treatment.
Although screening for breast cancer is highly recommended, some women end up having invasive treatment for tumours that are small and slow-growing and would not be fatal.
As a result, human expertise cannot be discounted, said Buzyn. "Diagnosis, prognosis, disease evaluation, all of these are carried out on the basis of basket of factors -- genes, risky behaviour, the patient's immune system and so on," she said.
Source-AFP